2019
DOI: 10.1111/bcp.14138
|View full text |Cite
|
Sign up to set email alerts
|

Using GRADE methodology to assess innovation of new medicinal products in Italy

Abstract: Aim: In April 2017 the Italian Medicine Agency (AIFA) developed new criteria to grant any new medicinal product with an innovative designation. The aim of this study is to describe this new model and how it works. Methods: A retrospective descriptive analysis was performed on the results of the assessment process of innovativeness of new medicinal products (or therapeutic indications) based on the AIFA's new innovation criteria (therapeutic need, added therapeutic value and quality of clinical evidence through… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
20
1
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(23 citation statements)
references
References 13 publications
1
20
1
1
Order By: Relevance
“…The choice of GRADE methodology was aimed at improving the transparency and reproducibility of the appraisal process; this structured and flexible methodological tool provides a systematic approach in the assessment and is meant to minimise biases and improve consistency of the decisions. 5 The innovativeness is appraised per indication, and the innovativeness status lasts 3 years. The appraisal model represents a common framework for all indications, even if safeguard clauses are provided for rare indications where the quality of the evidence is more likely to be lower.…”
Section: Strengths and Limitations Of This Studymentioning
confidence: 99%
See 1 more Smart Citation
“…The choice of GRADE methodology was aimed at improving the transparency and reproducibility of the appraisal process; this structured and flexible methodological tool provides a systematic approach in the assessment and is meant to minimise biases and improve consistency of the decisions. 5 The innovativeness is appraised per indication, and the innovativeness status lasts 3 years. The appraisal model represents a common framework for all indications, even if safeguard clauses are provided for rare indications where the quality of the evidence is more likely to be lower.…”
Section: Strengths and Limitations Of This Studymentioning
confidence: 99%
“…The choice of GRADE methodology was aimed at improving the transparency and reproducibility of the appraisal process; this structured and flexible methodological tool provides a systematic approach in the assessment and is meant to minimise biases and improve consistency of the decisions. 5 …”
Section: Introductionmentioning
confidence: 99%
“…Current proposals to address concerns include establishing meaningful minimum effectiveness levels for new oncology medicines to be funded at higher prices than current standards, first proposed in the United Kingdom in 2000 [40,41], defining what is meant by innovation [42], and implementing fair and transparent approaches toward the pricing of new oncology medicines proposed by European payers, the World Health Organization (WHO) and others although there are concerns with issues including fully costing R. & D [43][44][45]. Potential proposals also include re-looking at managed entry agreements (MEAs) with countries concerned they may not always be getting optimal discounts in practice with rebates continuing to be confidential [46,47]; however, balanced against increased opportunities of reimbursement with such schemes combined with the potential to gain valuable evidence of the performance new oncology medicines in routine clinical care [46,48].…”
Section: Introductionmentioning
confidence: 99%
“…The definition of innovation and novelty was not clear even in those HTAs where the agency explicitly considered these factors, which may explain some of the variability between agency decisions. Research is underway on how best to define and reward medical innovation [34,35], which may clarify and qualify the value of innovation in future reimbursement decisions.…”
Section: Discussionmentioning
confidence: 99%